CPT code 0016U designates a proprietary molecular diagnostic assay for detection and characterization of BCR–ABL1 major and minor breakpoint fusion transcripts performed by the University of Iowa, Department of Pathology or Asuragen on whole blood or bone marrow aspiration specimens. This PLA code matters nationally because BCR–ABL1 testing directly informs diagnosis, treatment selection, and monitoring for patients with BCR–ABL1–positive leukemias, where molecular results impact targeted therapy decisions and disease surveillance.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical and laboratory context, payer coverage considerations, common billing modifiers, and the typical service setting. The publication outlines benchmark elements and policy-relevant details that affect national coverage and billing for proprietary laboratory assays, including how PLA codes like 0016U are used to represent manufacturer- or lab-specific tests. The content highlights operational implications for laboratories and billing teams, and provides clarity on where this code fits within molecular diagnostic service lines.

This summary is intended for a national audience of clinicians, laboratory directors, and revenue cycle professionals seeking a clear, policy-oriented briefing on CPT code 0016U.